Výsledky vyhledávání - "Dann Ouizeman"

Akademický článek

Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome (IBS): Correlating H2 or CH4 production with severity of IBS

Autor: Philippe Onana Ndong, Hanae Boutallaka, Eugenia Marine‐Barjoan, Dann Ouizeman, Raja Mroue, Rodolphe Anty, Geoffroy Vanbiervliet, Thierry Piche

Publikováno v: JGH Open, Vol 7, Iss 4, Pp 311-320 (2023)

Abstract Background and Aim The prevalence and the role of small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) remain unclear, as the literature provides heterogeneous information on the subject. The aim of this study was t

Externí odkaz: https://doaj.org/article/e25348696373474fb3cf31d153da544b

Zobrazit plný text záznamu

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Autor: Xavier, Adhoute, Marie, De Matharel, Laurent, Mineur, Guillaume, Pénaranda, Dann, Ouizeman, Clemence, Toullec, Albert, Tran, Paul, Castellani, Armelle, Rollet, Valérie, Oules, Hervé, Perrier, Si Nafa, Si Ahmed, Marc, Bourliere, Rodolphe, Anty

Publikováno v: World Journal of Gastrointestinal Oncology. 14:1510-1527

Starting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two broad-spectrum tyrosine kinase inhibitors (TKIs), regorafenib (REG) and cabozantinib (CBZ), but no comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1153bd37db24ce97eb975299824611
https://doi.org/10.4251/wjgo.v14.i8.1510

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání